Jinshi Ya Pharmaceutical: Announcement on the wholly owned Sun Company passing the GMP compliance inspection of the drug
Jinshi Asia Pharmaceutical: Announcement on the Wholly-owned Sun Company Obtaining a High-tech Enterprise Certificate
Jinshi Asia Pharmaceutical: Announcement of Resolutions of the 6th Meeting of the Fifth Board of Directors
Jinshi Yayao: Announcement on the wholly-owned subsidiary obtaining a registration certificate for oseltamivir phosphate capsules
Jinshi Asia Pharmaceutical: Announcement of Resolutions of the Fifth Meeting of the Fifth Board of Supervisors
Jinshi Asia Pharmaceutical: Report for the third quarter of 2024
Jinshi Asia Pharmaceutical: Announcement of Resolutions of the Fifth Meeting of the Fifth Board of Directors
Jinshi Asia Pharmaceutical: Announcement on attending the 2024 Online Investor Group Reception Day and Semi-Annual Results Briefing in the Sichuan Region
Jinshi Ya Pharmaceutical: Summary table of non-operating capital expenditure and other related capital transactions for the first half year of 2024
Jinshi Asia Pharmaceutical: Announcement of Board Resolutions
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report Summary
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report
Jinshi Asia Pharmaceutical: Announcement of Supervisory Committee Resolutions
Sichuan Goldstone: Announcement of Annual Equity Distribution Implementation in 2023
Sichuan Goldstone: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Sichuan Goldstone: Legal Opinion on the 2023 Annual General Meeting of Shareholders of Sichuan Jinshi Asia Pharmaceutical Co., Ltd.
Sichuan Goldstone: 300434 Jinshi Asia Pharmaceutical Investor Relations Management Information 20240517
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Liu Chuwang)
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Zhu Jianwei)
Sichuan Goldstone: Announcement on the proposed renewal of financial auditors and internal control auditors in 2024
No Data